Skip to main content

Saturn Medic

Clinical Subject Page

Pneumocystis jirovecii pneumonia (PJP)

Pneumocystis jirovecii pneumonia (PCP) is an opportunistic fungal pneumonia caused by Pneumocystis jirovecii, occurring mainly in immunocompromised individuals.

Also called

PCP (Pneumocystis pneumonia)

ICD-10

B44.81

Specialty

Pulmonology

Onset

Acute

Reviewed

July 2026

On This Page

Overview

  • Pneumocystis Pneumonia (PJP) is one of the most common opportunistic infections in patients with:

    • HIV/AIDS
    • Organ transplantation
    • Hematologic malignancies
    • Long-term immunosuppressive therapy

    The infection causes:

    Diffuse alveolar inflammation → Impaired gas exchange → Progressive hypoxemia

Etiology & Risk Factors

Cause

  • Pneumocystis jirovecii

Risk Factors

  • HIV/AIDS (especially CD4 <200 cells/μL)
  • Prolonged corticosteroid therapy
  • Organ transplantation
  • Hematologic malignancies
  • Chemotherapy
  • Immunosuppressive medications
  • Primary immunodeficiency

Important Note

Pneumocystis Pneumonia (PJP) should always be suspected in immunocompromised patients with progressive dyspnea, dry cough, and hypoxemia.

Pathophysiology

Immunosuppression

Pneumocystis jirovecii infection

Diffuse alveolar colonization

Alveolar inflammation

Protein-rich foamy alveolar exudate

Impaired oxygen diffusion

Progressive hypoxemia

Respiratory failure (severe disease)

Key Concept

PJP causes diffuse alveolar injury resulting in severe hypoxemia rather than focal lobar consolidation.

Clinical Presentation

  • Symptoms

    • Progressive dyspnea
    • Dry cough
    • Fever
    • Fatigue
    • Reduced exercise tolerance
    • Chest discomfort

    Signs

    • Tachypnea
    • Tachycardia
    • Reduced oxygen saturation
    • Fine inspiratory crackles (may be absent)

    Severe Disease

    • Marked hypoxemia
    • Cyanosis
    • Respiratory distress
    • Respiratory failure

History Taking

    • Ask about:

      • HIV infection?
      • CD4 count?
      • Organ transplantation?
      • Long-term corticosteroid use?
      • Immunosuppressive medications?
      • Progressive shortness of breath?
      • Dry cough?
      • Fever?
      • Weight loss?
      • Previous PJP?
      • PJP prophylaxis?

Physical Examination

Look for:

  • Fever
  • Tachypnea
  • Tachycardia
  • Hypoxemia
  • Cyanosis

Chest Examination

May show:

  • Fine inspiratory crackles
  • Normal examination in early disease

Investigations of Pneumocystis Pneumonia (PJP)

  • Chest Imaging

    Chest X-ray

    May show:

    • Diffuse bilateral interstitial or perihilar infiltrates

    May be normal early in the disease.

    High-Resolution CT (HRCT)

    May show:

    • Diffuse bilateral ground-glass opacities
    • Interstitial infiltrates
    • Pulmonary cysts (occasionally)

    Laboratory Tests

    • CBC
    • LDH (often elevated)
    • HIV testing when appropriate
    • Arterial blood gas

    Microbiological Diagnosis

    Obtain respiratory specimens for:

    • PCR for Pneumocystis jirovecii
    • Microscopy with special stains
    • Bronchoalveolar lavage (BAL) if sputum is nondiagnostic

Diagnosis of Pneumocystis Pneumonia (PJP)

1. Compatible Clinical Features

  • Progressive dyspnea
  • Dry cough
  • Fever

2. Compatible Imaging

  • Bilateral diffuse infiltrates
  • Ground-glass opacities

3. Microbiological Confirmation

Using:

  • PCR
  • Microscopy
  • Bronchoalveolar lavage specimens

Important Note

Definitive diagnosis requires identification of Pneumocystis jirovecii in respiratory specimens.

Management of Pneumocystis Pneumonia (PJP)

  • Main Goals

    • Eradicate infection
    • Improve oxygenation
    • Prevent respiratory failure
    • Treat underlying immunosuppression

    First-Line Therapy

    • Trimethoprim-sulfamethoxazole (TMP-SMX)

    Adjunctive Corticosteroids

    Recommended for moderate-to-severe PJP with significant hypoxemia.

    Supportive Management

    • Oxygen therapy
    • Mechanical ventilation if required
    • Optimize treatment of the underlying immunodeficiency

    Prevention

    TMP-SMX prophylaxis is recommended for high-risk patients (e.g., HIV with CD4 <200 cells/μL).

Complications of Pneumocystis Pneumonia (PJP)​

  • Acute respiratory failure
  • Acute respiratory distress syndrome (ARDS)
  • Pneumothorax
  • Secondary bacterial infection
  • Mechanical ventilation
  • Death

Prognosis of Pneumocystis Pneumonia (PJP)

  • Prognosis is excellent with early diagnosis and treatment.
  • Delayed diagnosis increases mortality.
  • Prognosis is worse in:
    • Severe hypoxemia
    • Delayed treatment
    • Non-HIV immunocompromised patients
  • Appropriate prophylaxis markedly reduces the incidence of PJP.

Key Points / Clinical Pearls

  • Pneumocystis jirovecii pneumonia (PJP)​ is an opportunistic fungal pneumonia caused by Pneumocystis jirovecii.
  • It occurs mainly in immunocompromised patients, especially those with HIV/AIDS (CD4 <200 cells/μL).
  • Progressive dyspnea, dry cough, fever, and hypoxemia are classic features.
  • HRCT typically shows diffuse bilateral ground-glass opacities.
  • Chest X-ray may be normal early in the disease.
  • PCR or microscopy of respiratory specimens confirms the diagnosis.
  • TMP-SMX is the first-line treatment and prophylaxis.
  • Adjunctive corticosteroids are indicated in moderate-to-severe PJP with hypoxemia.
  • Pneumothorax is a recognized complication of PJP.